I'm Jenna, a 36-year-old married mother of one son, and I have neuroendocrine cancer (NETs). It is a rare type of cancer, and 60% of the time, once a person…
The primary outcome from the Phase III NETTER-2 clinical trial as reported recently in Globe Newswire, was heralded as extending progression free survival from 8.5 months to 22.8. The participants…
November 10 is recognized as World Neuroendocrine Tumor (NET) Cancer Day, a time to spread awareness about neuroendocrine tumors, a group of rare cancers, among the medical field and in…
The National Medical Products Administration (NMPA) of China has recently approved surufatinib for drug registration for the treatment of advanced pancreatic neuroendocrine tumors (pNETs). HUTCHMED Limited recently announced the news,…
The Patient-Centered Outcomes Research Institute (PCORI) has announced that it will be contributing funding for four new studies focused on four different rare diseases. The funding will top out at…
According to a story from businesswire.com, the biopharmaceutical company Ipsen recently presented a total of 9 study abstracts at the recent 18th annual conference of the European Neuroendocrine Tumor Society…
While 2020 was a challenging year for many people in the US, the life of three year old Lelani was in particular disarray. She was in and out of the…
Patients with inoperable or metastasized neuroendocrine tumors (NETs) may now benefit from recently FDA approved peptide receptor radionuclide therapy (PRRT) according to a recent article in MedPage Today. The…
Surufatinib was recently granted Orphan Drug designation by the FDA. This drug was made for the treatment of pancreatic neuroendocrine tumors (PanNETs). It was created by Hutchison China MediTech…
According to a story from Central Charts, the drug developer Crinetics Pharmaceuticals, Inc. recently issued an announcement revealing that the company has begun the initialization of a Phase 1 clinical…
According to a story from pm360online.com, the Novartis company Advanced Accelerator Applications S.A. recently announced that Health Canada has issued approval for Lutathera™ as a treatment for gasteroenteropancreatic neuroendocrine tumors…
Neuroendocrine tumors are growths which form from neuroendocrine cells in various places throughout the body. They can occur in the gastrointestinal track, the pancreas, the lungs, the thymus, and other…
Joe Marksteiner, a 22-year Air Force veteran and former gymnast, won a title at the 2013 World Powerlifting Championships at the age of 60. This year, now at 65, he…
On August 16th, 2018, Aretha Franklin, the "Queen of Soul," passed away at age 76. Aretha will be immortalized for generations because of the success of her classic soul ballads…
Novartis has teamed up with Numinous Games to develop Galaxies of Hope, an app that is designed to support the neuroendocrine tumour (NET) community. You can read the original source…
© Copyright 2024 Patient Worthy
Sign Up With a Patient Worthy Account and Share Your Rare Story
- OR -
Make a difference, share your experiences and get paid. Opt-in and join Patient Worthy's panel for paid opportunities such as surveys, market research, patient advisory panels and more.
- OR -
Make a difference, share your experiences and get paid. Opt-in and join Patient Worthy's panel for paid opportunities such as surveys, market research, patient advisory panels and more.
